Mivebresib (ABBV-075)

Mivebresib (ABBV-075) is a small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor being studied in a Phase 1 clinical trial in patients with advanced hematologic malignancies and solid tumors.

Type of Molecule

Small Molecule

Target

BET

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Acute Myeloid Leukemia (AML) n/a
Phase 1
Solid Tumors n/a
Phase 1
Multiple Myeloma (MM) n/a
Phase 1